Associate Scientist I, Bioassay Development, Gene Therapy - United States
- The Analytical Development department is seeking a motivated college graduate to join a team of scientists to support the application of novel technologies in characterizing AAV gene therapy products.
- Under the guidance of Ph.D. scientists, the individual will evaluate novel analytical platforms to characterize biochemical and biophysical properties of the AAV gene therapy vectors, including empty virus particles, aggregation of virus particles, and quantification of particulates.
- The analytical platform to be evaluated includes, but not limited to, analytical ultracentrifugation (AUC), spectroscopy (UV, Raman, IR, etc.), as well as more traditional HPLC/UPLC platforms.
- Implementation of these new analytical methods will be essential for the development of robust AAV gene therapy products and for the successful regulatory filings of these much needed therapies.
- The successful candidates shall hold BS degree from Biophysics, Analytical Chemistry, Chemical Engineering, Bio-engineering, or other related fields, and has completed biophysics and analytical chemistry course work, and demonstrated good understanding in these disciplines.
- Having previous lab experience in bio science field is required.
- Knowledge of protein characterization with spectroscopy is preferred
B.S. in Biophysics, Analytical Chemistry, Chemical Engineering, Bio-engineering, or other related fields in science or engineering.
- Through cutting-edge science and medicine, our company discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.
- Our company is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis (MS), has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
- Our company also manufactures and commercializes biosimilars of advanced biologics.
- Our global organization of nearly 7,000 employees is committed to a single mission: making a meaningful difference in the lives of patients with few or no treatment options.
- Our company was founded in 1978 and today serves patients in nearly 70 countries.
- We aspire to have the greatest impact on patients and science of any biotechnology company in the history of our industry.
- To us, that means creating novel medicines that benefit individuals and society, and bringing new scientific understanding to diseases for which there are no adequate treatments.
- For nearly two decades our company has led in the research and development of new therapies to treat MS, including the most prescribed oral treatment in the world.
- Now our research is driving revolutionary new MS treatments with the goal of reversing or even repairing damage caused by the disease.
- We are now applying our neurological expertise to solve some of most challenging and complex diseases of the brain, including Alzheimer’s disease, Parkinson’s disease, and ALS.
- As we uncover new insights into human biology, our company is employing cutting-edge technologies to discover potential treatments for rare and genetic disorders.
- Our company is revolutionizing biologic manufacturing, developing the industry’s most advanced plants and processes.
- This expertise is used to produce both original innovative therapies and bio similar that expand patient access to lower-cost medicines.
Our Corporate Citizenship
- The same intellectual discipline and passion that drives our science is reflected in our corporate citizenship, environmental sustainability, and commitment to diversity and inclusion.
- As a company, we are focused on improving science education and limiting the impact of our company on the environment.